Glatiramer Acetate (Copaxone) Modulates Platelet Activation and Inhibits Thrombin-Induced Calcium Influx: Possible Role of Copaxone in Targeting Platelets during Autoimmune Neuroinflammation
Background Glatiramer acetate (GA, Copaxone, Copolymer-1) is an FDA approved drug for the treatment of MS and it is very effective in suppressing neuroinflammation in experimental autoimmune encephalitis (EAE), an animal model of MS. Although this drug was designed to inhibit pathogenic T cells, the exact mechanism of EAE/MS suppression by GA is still not well understood. Previously we presented evidence that platelets become activated and promote neuroinflammation in EAE, suggesting a possible pathogenic role of platelets in MS and EAE. We hypothesized that GA could inhibit neuroinflammation by affecting not only immune cells but also platelets. Methodology/Principal Findings We investigated the effect of GA on the activation of human platelets in vitro: calcium influx, platelet aggregation and expression of activation markers. Our results in human platelets were confirmed by in-vitro and in-vivo studies of modulation of functions of platelets in mouse model. We found that GA inhibited thrombin-induced calcium influx in human and mouse platelets. GA also decreased thrombin-induced CD31, CD62P, CD63, and active form of αIIbβ3 integrin surface expression and formation of platelet aggregates for both mouse and human platelets, and prolonged the bleeding time in mice by 2.7-fold. In addition, we found that GA decreased the extent of macrophage activation induced by co-culture of macrophages with platelets. Conclusions GA inhibited the activation of platelets, which suggests a new mechanism of GA action in suppression of EAE/MS by targeting platelets and possibly preventing their interaction with immune cells such as macrophages. Furthermore, the reduction in platelet activation by GA may have additional cardiovascular benefits to prevent thrombosis.
References
[1]
Langer HF, Chavakis T (2013) Platelets and neurovascular inflammation. Thromb Haemost 110.
[2]
Behari M, Shrivastava M (2013) Role of platelets in neurodegenerative diseases: a universal pathophysiology. Int J Neurosci 123: 287–299. doi: 10.3109/00207454.2012.751534
[3]
Horstman LL, Jy W, Ahn YS, Zivadinov R, Maghzi AH, et al. (2010) Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation 7: 10. doi: 10.1186/1742-2094-7-10
[4]
Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, et al. (2003) Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 9: 61–67. doi: 10.1038/nm810
[5]
Lang PA, Contaldo C, Georgiev P, El-Badry AM, Recher M, et al. (2008) Aggravation of viral hepatitis by platelet-derived serotonin. Nat Med 14: 756–761. doi: 10.1038/nm1780
[6]
Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, et al. (2010) Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327: 580–583. doi: 10.1126/science.1181928
[7]
Semple JW, Italiano JE Jr, Freedman J (2011) Platelets and the immune continuum. Nat Rev Immunol 11: 264–274. doi: 10.1038/nri2956
Sheremata WA, Jy W, Horstman LL, Ahn YS, Alexander JS, et al. (2008) Evidence of platelet activation in multiple sclerosis. J Neuroinflammation 5: 27. doi: 10.1186/1742-2094-5-27
[10]
Langer HF, Choi EY, Zhou H, Schleicher R, Chung KJ, et al. (2012) Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res 110: 1202–1210. doi: 10.1161/circresaha.111.256370
[11]
Sotnikov I, Veremeyko T, Starossom SC, Barteneva N, Weiner HL, et al. (2013) Platelets recognize brain-specific glycolipid structures, respond to neurovascular damage and promote neuroinflammation. PLoS One 8: e58979. doi: 10.1371/journal.pone.0058979
[12]
Johnson KP (2010) Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update. Expert Opin Drug Metab Toxicol 6: 643–660. doi: 10.1517/17425251003752715
[13]
Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, et al. (2007) Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 13: 935–943. doi: 10.1038/nm1620
[14]
Liu J, Johnson TV, Lin J, Ramirez SH, Bronich TK, et al. (2007) T cell independent mechanism for copolymer-1-induced neuroprotection. Eur J Immunol 37: 3143–3154. doi: 10.1002/eji.200737398
[15]
Kala M, Rhodes SN, Piao WH, Shi FD, Campagnolo DI, et al. (2010) B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol 221: 136–145. doi: 10.1016/j.expneurol.2009.10.015
[16]
Begum-Haque S, Sharma A, Christy M, Lentini T, Ochoa-Reparaz J, et al. (2010) Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 219: 47–53. doi: 10.1016/j.jneuroim.2009.11.016
[17]
Elgart GW, Sheremata W, Ahn YS (1997) Cutaneous reactions to recombinant human interferon beta-1b: the clinical and histologic spectrum. J Am Acad Dermatol 37: 553–558. doi: 10.1016/s0190-9622(97)70170-1
[18]
Bosca I, Bosca M, Belenguer A, Evole M, Hernandez M, et al. (2006) Necrotising cutaneous lesions as a side effect of glatiramer acetate. J Neurol 253: 1370–1371. doi: 10.1007/s00415-006-0233-9
[19]
Segal JB, Powe NR (2006) Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 4: 2377–2383. doi: 10.1111/j.1538-7836.2006.02147.x
[20]
Scull CM, Hays WD, Fischer TH (2010) Macrophage pro-inflammatory cytokine secretion is enhanced following interaction with autologous platelets. J Inflamm (Lond) 7: 53. doi: 10.1186/1476-9255-7-53
[21]
Mantovani A, Garlanda C (2013) Platelet-macrophage partnership in innate immunity and inflammation. Nat Immunol 14: 768–770. doi: 10.1038/ni.2666
[22]
Greene TK, Schiviz A, Hoellriegl W, Poncz M, Muchitsch EM, et al. (2010) Towards a standardization of the murine tail bleeding model. J Thromb Haemost 8: 2820–2822. doi: 10.1111/j.1538-7836.2010.04084.x
[23]
Nakano Y, Oshima T, Ozono R, Ueda A, Oue Y, et al. (2002) Estrogen replacement suppresses function of thrombin stimulated platelets by inhibiting Ca(2+) influx and raising cyclic adenosine monophosphate. Cardiovasc Res 53: 634–641. doi: 10.1016/s0008-6363(01)00410-2
[24]
Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, et al. (2000) Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 6: 255–266. doi: 10.1177/135245850000600407
[25]
Chronos NA, Goodall AH, Wilson DJ, Sigwart U, Buller NP (1993) Profound platelet degranulation is an important side effect of some types of contrast media used in interventional cardiology. Circulation 88: 2035–2044. doi: 10.1161/01.cir.88.5.2035
[26]
Moroi M, Jung SM, Shinmyozu K, Tomiyama Y, Ordinas A, et al. (1996) Analysis of platelet adhesion to a collagen-coated surface under flow conditions: the involvement of glycoprotein VI in the platelet adhesion. Blood 88: 2081–2092.
[27]
Stefanini L, Ye F, Snider AK, Sarabakhsh K, Piatt R, et al. (2014) A talin mutant that impairs talin-integrin binding in platelets decelerates alphaIIbbeta3 activation without pathological bleeding. Blood.
[28]
Lenting PJ, Westerlaken GH, Denis CV, Akkerman JW, Meyaard L (2010) Efficient inhibition of collagen-induced platelet activation and adhesion by LAIR-2, a soluble Ig-like receptor family member. PLoS One 5: e12174. doi: 10.1371/journal.pone.0012174
[29]
Veremeyko T, Siddiqui S, Sotnikov I, Yung A, Ponomarev ED (2013) IL-4/IL-13-Dependent and Independent Expression of miR-124 and Its Contribution to M2 Phenotype of Monocytic Cells in Normal Conditions and during Allergic Inflammation. PLoS One 8: e81774. doi: 10.1371/journal.pone.0081774
